Fig. 2: Prognostic impact of high MIPI-c or high p53 expression on outcome stratified by trial groups. | Leukemia

Fig. 2: Prognostic impact of high MIPI-c or high p53 expression on outcome stratified by trial groups.

From: Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

Fig. 2

Kaplan–Meier estimates of FFS (A, C) and OS (B, D) among patients treated in the MCL Younger (A, B) and MCL Elderly (C, D) trial stratified by the presence of high MIPI-c or p53 expression >50% (high-risk disease) compared to low, low-intermediate or high-intermediate MIPI-c and p53 expression ≤50% (low-risk disease). The number at risk is based on all classifiable patients.

Back to article page